The company's technology allows for the conversion of various cell types into functional chondrocytes, which can spontaneously form cartilage. This provides healthcare professionals with a safe, efficient, and scalable source of therapeutic cells for treating osteoarthritis. Chondrogenix is a wholly owned subsidiary of Mogrify Ltd, a Cambridge-based company specializing in the development of cell therapies.